NCT04596033 - TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

June 27, 2022

Study Completion Date

June 27, 2022

Conditions

MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma of Head and NeckUrothelial CarcinomaRenal Cell CarcinomaSmall-cell Lung CancerCutaneous Squamous Cell CarcinomaAnal Squamous Cell CarcinomaMerkel Cell Carcinoma

Interventions

BIOLOGICAL

GEN-011

Personalized neoantigen adoptive cell therapy (ACT)

DRUG

IL-2

Cytokine

DRUG

Fludarabine

Lymphodepletion drug

DRUG

Cyclophosphamide

Lymphodepletion drug

Trial Locations (8)

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

33612

Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute, Nashville

60637

University of Chicago Medical Center, Chicago

77030

MD Anderson Cancer Center, Houston

85234

Banner MD Anderson Cancer Center, Gilbert

02215

Dana Farber Cancer Institute, Boston